Prezista licence extension

Janssen-Cilag has launched two new strengths of Prezista (darunavir) tablets: 400mg and 600mg.

The Prezista 400mg tablets are licensed for use with low dose ritonavir in combination with other antiretrovirals for the treatment of HIV in antiretroviral naïve patients.

The 600mg tablets, along with the existing 300mg tablets, are available for the treatment of HIV with low dose ritonavir in combination with other antiretrovirals, in treatment experienced adult patients, including those that have been highly pre-treated. The Prezista 600mg tablet has been launched to reduce patients' pill burden.

The recommended dosage in treatment naive patients is 800mg once daily with ritonavir 100mg once daily.

View Prezista drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases